Medical Costs Are Rising at Their Fastest Rate in 15 Years — and GLP-1 Drugs Are Restructuring Every Adjacent Healthcare Market

GLP-1 Drugs Are Restructuring the Economics of Every Adjacent Healthcare Market

The commercial footprint of GLP-1 receptor agonists has expanded beyond the obesity and diabetes treatment categories that generated initial adoption, and the breadth of that expansion is producing secondary effects across adjacent healthcare markets that most sector planning models have not yet fully incorporated. The CMS decision to select Wegovy for the 2026 Medicare price negotiation cycle — with a negotiated price taking effect January 2028 — established the regulatory precedent that the GLP-1 category will not remain exempt from the pricing mechanisms reshaping the rest of the pharmaceutical market. But the more commercially significant near-term dynamic is not the 2028 price ceiling itself; it is the evidence accumulating that GLP-1 treatment at population scale reduces downstream utilization of cardiovascular interventions, joint replacement surgeries, sleep apnea devices, and other high-cost care categories that collectively represent a much larger share of US and European healthcare spending than the GLP-1 drugs themselves. Insurance actuaries are beginning to quantify that reduced downstream cost, which creates a commercial argument for broader coverage that partially offsets the per-patient drug cost — and which fundamentally changes the payer calculus that had been limiting GLP-1 access to patients meeting strict BMI and comorbidity thresholds. For medical device companies, hospital systems, and procedure-based specialty practices across the US and Europe, the GLP-1 volume curve is creating a planning horizon problem: at what rate does GLP-1 population penetration translate into measurable utilization decline in the downstream care categories that represent their core revenue, and over what timeline does that translation occur?

The medtech sector's response to this pressure is visible in the M&A and private equity activity patterns documented by Deloitte for 2026: PE investment is concentrating on interventional, minimally invasive, and intelligence-driven solutions in cardiology, neurotechnology, surgical robotics, and medtech biologics — precisely the categories whose clinical complexity and physician dependency make them most resistant to the GLP-1-driven utilization decline affecting more straightforward procedural categories. The surgical robotics segment's continued growth despite broader medtech market softness reflects a dual dynamic: procedures that require robotic assistance are both clinically more complex than GLP-1 prevention can address and demonstrate enough cost-efficiency and outcome superiority over conventional surgery to justify the capital investment even in a tightening reimbursement environment. For European health systems making capital allocation decisions about surgical robotics platforms, the GLP-1 downstream utilization question is therefore not a reason to defer investment but rather a reason to concentrate it on the highest-complexity, highest-reproducibility procedure categories where the investment thesis is insulated from GLP-1 effects.

AI in Life Sciences Has Moved From Pilot Status to Infrastructure — With Uneven Results

Nearly 80 percent of life sciences executives surveyed in Deloitte's 2026 outlook recognize that future competitiveness depends on how effectively organizations harness AI — with 53 percent of medtech executives specifically identifying AI-enabled platforms as a key growth driver. The critical distinction emerging in 2026 is between organizations that deployed AI as a pilot initiative during 2023 and 2024 and are now struggling to realize commercial returns, and those that embedded AI into core operational processes from the outset and are generating measurable productivity gains. In pharmaceutical R&D, AI-supported study design and bioanalytics are reducing development timelines in the organizations that have achieved what Takeda's Chief Data and Technology Officer describes as the necessary coexistence of discipline and innovation — the unglamorous work of cleaning and connecting data pipelines before deploying the AI that runs on top of them. In revenue cycle management, AI-driven automation of prior authorization, coding, and denials management is delivering the most consistent near-term ROI, because these back-office functions have the structured data and clear outcome metrics that make AI performance measurable and improvable.

The European regulatory environment is adding a layer of compliance complexity to AI deployment in healthcare that the US market does not yet match. The EU AI Act's medical-device-adjacent provisions — which classify AI systems performing diagnostic or therapeutic assistance as high-risk systems subject to mandatory conformity assessments, transparency obligations, and human oversight requirements — are creating certification and documentation burdens for the European market launches of AI-enabled medtech products that are substantially heavier than the FDA's current Software as a Medical Device framework imposes in parallel. For companies developing AI-enabled diagnostic or therapeutic products for simultaneous US and European launch, the regulatory divergence between FDA SaMD guidance and EU AI Act requirements is creating a product design tension that the most strategically positioned organizations are resolving by designing to the stricter standard from the outset, rather than building to the FDA standard and then retro-fitting European compliance.

The Ambulatory Shift Is Accelerating — and It Is Permanent

The migration of procedures from hospital inpatient settings to outpatient and ambulatory surgical centers is one of the structural trends with the longest runway and the most consistent commercial evidence in US and European healthcare markets. CMS's 2026 Hospital Outpatient Prospective Payment System final rule reinforces the direction by expanding the ambulatory surgical center covered procedure list and continuing to phase out the inpatient-only list — moves that open higher-acuity procedures including cardiac ablation to lower-cost ambulatory settings when clinically appropriate. The commercial implication for medtech companies is the need to redesign economic value propositions and product configurations for the ASC environment, where physician preference, per-procedure economics, and room turnover speed matter more than the hospital-centric metrics of capital equipment capability and institutional volume contracts that have historically anchored medtech commercial models. For European health systems pursuing their own version of the ambulatory shift — driven by workforce shortages that make hospital-based procedure delivery increasingly unsustainable at projected volumes — the US ASC model's commercial and operational infrastructure provides a decade of evidence to draw on, even if the specific regulatory and reimbursement frameworks differ significantly across EU member states.